Article

Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2

2022-07-15

Abstract excerpt

<h4>Summary</h4> Some COVID-19 patients are unable to clear their infection or are at risk of severe disease, requiring treatment with neutralising monoclonal antibodies (nmAb) and/or antivirals. The rapid roll-out of novel therapeutics means there is limited understanding of the likely genetic barrier to drug resistance. Unprecedented genomic surveillance of SARS-CoV-2 in the UK has enabled a genome-first approa...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 50ca9df9-670d-5642-98d6-b04d6d26bc17
DOI: 10.1101/2022.07.14.500063

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2DOI 10.1101/2022.07.14.500063Read

Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy.Semantic proximity Read

SARS-CoV-2 evolution and evasion from multiple antibody treatments in a cancer patientSemantic proximity Read

Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variantsSemantic proximity Read

Complex intra-host SARS-CoV-2 evolution following monoclonal antibody pre-exposure prophylaxisSemantic proximity Read

Deep mining of early antibody response in COVID-19 patients yields potent neutralisers and reveals high level of convergenceSemantic proximity Read

SABRes: A tool for in silico detection of drug resistance conferring mutations in SARS-CoV-2 genomesSemantic proximity Read

Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapySemantic proximity Read

RECOMBINANT HUMAN MONOCLONAL ANTIBODIES CASIRIVIMAB/IMDEVIMAB USE IN INHIBITION OF THE SARS-CoV-2 VIRUS INFECTIONSemantic proximity Read

SABRes: in silico detection of drug resistance conferring mutations in subpopulations of SARS-CoV-2 genomes.Semantic proximity Read

A Possible Role of Remdesivir and Plasma Therapy in the Selective Sweep and Emergence of New SARS-CoV-2 VariantsSemantic proximity Read

SARS-CoV-2 Omicron Variants and Their Susceptibility Towards Monoclonal Antibodies in a Swedish Cohort During 2022-23, Studied by Next-Generation SequencingSemantic proximity Read

Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patientsSemantic proximity Read